Background
UniProt:P01112 encodes a protein implicated in various cellular processes relevant to oncogenesis, including cell signaling and proliferation. In the context of urothelial carcinoma, a malignancy arising from the urothelial lining of the bladder and urinary tract, molecular targets remain limited, and novel candidates are needed to improve therapeutic options. The putative role of UniProt:P01112 in urothelial carcinoma biology is suggested by its differential expression in tumor tissue compared to normal urothelium, indicating potential involvement in tumor progression or maintenance. However, this target remains uncharacterized in clinical development, and its functional relevance in urothelial carcinoma warrants experimental validation.
Data-mining rationale
Our approach cross-referenced the reviewed human protein entries in UniProt associated with "urothelial carcinoma" against 74 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). UniProt:P01112 emerged as a candidate due to its recurrent appearance in expression profiling studies of urothelial carcinoma samples. These datasets include GDS:200292216, GDS:200245118, GDS:200253531, GDS:200201395, and GDS:200181962, which collectively profile gene expression patterns in urothelial carcinoma versus normal tissue or across tumor subtypes. This integrative data-mining strategy highlights UniProt:P01112 as a putative target that may contribute to disease biology and thus merits further investigation.
Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the widespread adoption of modern empirical-Bayes statistical methods such as limma, which improve the detection of differentially expressed genes by borrowing strength across genes and controlling for variance more effectively. Additionally, earlier studies often lacked rigorous multiple-testing correction procedures like the Benjamini-Hochberg false discovery rate (FDR) adjustment, increasing the risk of false positives or negatives. Consequently, the potential significance of UniProt:P01112 in urothelial carcinoma may have been obscured or underestimated in prior analyses. Re-analysis of these datasets with updated statistical frameworks could clarify the gene’s differential expression status and strengthen its candidacy.
Reasoning for further validation
To substantiate UniProt:P01112 as a putative target in urothelial carcinoma, several experimental steps are recommended. First, re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR control will provide a robust statistical assessment of differential expression. Second, validating the top differentially expressed genes, including UniProt:P01112, by quantitative PCR in independent urothelial carcinoma cohorts will confirm reproducibility. Third, assessing tissue specificity through resources such as GTEx and the Human Protein Atlas will determine the expression pattern of UniProt:P01112 in normal versus malignant urothelial tissues. Fourth, pathway analysis using STRING or OmniPath can contextualize UniProt:P01112 within relevant signaling networks, potentially revealing mechanistic roles. Finally, if validated, evaluating druggability via databases like DGIdb and ChEMBL could inform the feasibility of targeting UniProt:P01112 therapeutically. Collectively, these investigations will clarify the biological and translational relevance of UniProt:P01112 in urothelial carcinoma.